Middle-Income Countries consider voiding hepatitis C drug patents

This page is an archive. Its content may no longer be accurate and was last updated on the original publication date. It is intended for reference and as a historical record only. For hep C questions, call Help4Hep BC at 1-888-411-7578.

Sovaldi (sofosbuvir) bottle
Gilead Sciences SOVALDI (sofosbuvir) tablets are effective but beyond the reach of most patients, unless they are insured, or subsidized by their government or a charity

Physician, patient, and health justice groups including the Initiative for Medicines, Access and Knowledge (I-MAK) are mounting legal challenges to Gilead Sciences’ patent to sofosbuvir in several middle-income countries including Argentina, Brazil, China, Russia and Ukraine. Read more…

http://www.nytimes.com/2015/05/20/business/high-cost-of-hepatitis-c-drug-prompts-a-call-to-void-its-patents.html

Leave a Reply